Search Results - Ottensmeier, C.H.H.

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    177P Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour

    177P Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour by Tanis, J-B., McCann, K., Castaneda, E., Thomas, J., Bailey, A., Pickering, J., Singh, P., Tiwari, A., Currall, E., Chudley, L., Cave, J., Takhar, A., Schoenberger, S.P., Greenbaum, J., Savelyeva, N., Vijayanand, P., Seumois, G., Ottensmeier, C.H.H.

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT

    155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT by Klinghammer, K., Saba, N.F., Castelluci, E., Colevas, A.D., Rutkowski, T., Greil, R., Thurner, D., Müller-Richter, U., Di Giacomo, A.M., Grewal, J., Ottensmeier, C.H.H., Atasoy, A., Shpyro, S., Brück, P., Dias, J., Ganser, C., Türeci, Ö., Sahin, U.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: